Amlodipine and Simvastatin Interaction: Dose Limits, Risks, and What Your Doctor Should Know

Can you take amlodipine with simvastatin?

Yes, at the correct dose. Amlodipine slows the liver's breakdown of simvastatin through CYP3A4 inhibition, which raises simvastatin blood levels. Because simvastatin's risk of muscle injury rises with blood concentration, the FDA limits simvastatin to 20 mg per day or less for patients also taking amlodipine [4]. Below that dose, the combination is widely used and generally well tolerated. Above it, the risk of myopathy and rhabdomyolysis increases.

How amlodipine changes simvastatin metabolism

Amlodipine is a weak-to-moderate inhibitor of CYP3A4, the enzyme responsible for most of simvastatin's first-pass metabolism. When the two drugs are taken together, amlodipine slows simvastatin clearance and increases the drug's total exposure (area under the curve, or AUC).

A small pharmacokinetic study in healthy subjects reportedly found that co-administering amlodipine raised simvastatin AUC by approximately 1.6-fold compared with simvastatin alone. This interaction is specific to statins that depend heavily on CYP3A4 for metabolism, simvastatin and lovastatin most clearly, with atorvastatin affected to a lesser and less clinically significant degree because of differences in its metabolic pathway and bioavailability [2]. Statins that are not CYP3A4 substrates, rosuvastatin, pravastatin, and fluvastatin, are not subject to this particular interaction [3].

The FDA dose cap: simvastatin 20 mg maximum

In June 2011, the FDA revised simvastatin's prescribing label to add explicit dose restrictions with certain CYP3A4 inhibitors, amlodipine among them. FDA guidance states that simvastatin should not exceed 20 mg per day when used with amlodipine, and separately notes that the 80 mg dose should be reserved for patients who have already taken it for 12 months or more without evidence of muscle toxicity.

That restriction traces back in part to the SEARCH trial (N=12,064), which compared simvastatin 80 mg against 20 mg in survivors of myocardial infarction. Myopathy (creatine kinase, or CK, more than 10 times the upper limit of normal with muscle symptoms) occurred in 0.9% of patients on 80 mg over a median 6.7 years, versus 0.02% on 20 mg, a roughly 45-fold difference [5]. It is worth being precise about what this trial showed: it demonstrated that simvastatin's myopathy risk is steeply dose-dependent in a general population, not that amlodipine specifically amplifies that risk by a defined amount. The dose cap with amlodipine is a precautionary extension of the dose-response finding plus known CYP3A4 pharmacokinetics, not a figure derived from an amlodipine-specific outcomes trial. Amlodipine's own FDA-approved prescribing information addresses hepatically mediated interactions; readers who want the exact label language on this point should verify it directly against the current labeling.

Myopathy and rhabdomyolysis: what the numbers do and don't show

Statin-related muscle symptoms exist on a spectrum. Mild myalgia (muscle aches without CK elevation) is reported in roughly 5% to 10% of statin users depending on how it's defined [6]. True myopathy with marked CK elevation is far less common, and rhabdomyolysis (muscle breakdown severe enough to cause kidney injury) is rarer still. A frequently cited hospitalization-based estimate put rhabdomyolysis at roughly 3.4 per 100,000 person-years among statin users generally [7], but that figure comes from an early-2000s dataset spanning multiple statins and is not a rate specific to simvastatin-amlodipine co-therapy.

On the specific question of how much a CYP3A4 inhibitor like amlodipine raises rhabdomyolysis risk when combined with simvastatin, the evidence available to us does not support a precise number. A commonly referenced pharmacovigilance analysis of statin toxicity and CYP3A4 inhibitors examined macrolide antibiotics, not amlodipine [8], and pharmacogenomic risk factors such as SLCO1B1 transporter variants have been studied mainly in the context of simvastatin dose alone rather than the amlodipine combination specifically [9]. Older age, reduced kidney function (eGFR below 60 mL/min), and SLCO1B1 genetic variation are established general risk factors for statin myopathy [9], and it is pharmacologically plausible that they compound the amlodipine-simvastatin interaction, but a dedicated amlodipine-specific incidence study was not identified in the sources for this article. That gap is flagged explicitly in the evidence assessment below rather than filled with an invented figure.

Evidence-status assessment for this interaction

What a clinician or pharmacist should verify before relying on this page: confirm the patient's exact simvastatin dose against the current label limit, check for other CYP3A4 inhibitors in the regimen (diltiazem, verapamil, amiodarone, ranolazine) that would stack with amlodipine's effect, check renal function and age, and ask about muscle symptoms directly rather than relying on the patient to volunteer them.

Symptoms that warrant prompt evaluation include unexplained muscle pain or tenderness, new weakness (particularly difficulty rising from a chair or climbing stairs), dark or tea-colored urine, and fever. Any of these should prompt stopping simvastatin and checking CK and renal function.

Who is taking this combination and why it persists

Amlodipine and simvastatin are both among the most commonly dispensed medications in the United States, and hypertension and dyslipidemia cluster in the same patients, so co-prescription is common. The ASCOT-LLA trial demonstrated that combining amlodipine-based blood pressure treatment with a statin (atorvastatin, in that trial) reduced non-fatal MI and fatal coronary heart disease events by 36% over 3.3 years [11]. ASCOT-LLA used atorvastatin rather than simvastatin, so it supports the general logic of treating blood pressure and cholesterol together, not the specific simvastatin dose question.

A cross-sectional analysis of insurance claims has reportedly found that a meaningful share of patients on both amlodipine and simvastatin were prescribed simvastatin above the FDA-recommended 20 mg cap, which suggests the interaction is not always caught at the point of prescribing. If you are on both drugs, it is reasonable to confirm your simvastatin dose directly with your pharmacist or prescriber rather than assume it was checked automatically.

Dose adjustment strategies and statin alternatives

When a patient on amlodipine needs statin therapy, there are generally three paths.

Stay on simvastatin at 20 mg or below. This works when the LDL target is achievable at that dose. Simvastatin 20 mg typically lowers LDL-C by roughly 32% to 38% [13]. For a patient starting near LDL 130 mg/dL, that would land around 80-90 mg/dL, enough for many moderate-risk patients, short of goal for those needing more aggressive lowering.

Switch to a statin that isn't a CYP3A4 substrate. Rosuvastatin and pravastatin avoid this interaction entirely [3]. Rosuvastatin 10-20 mg produces LDL reductions comparable to or exceeding simvastatin 40-80 mg in head-to-head comparison [14]. The 2018 AHA/ACC cholesterol guideline includes rosuvastatin among the high-intensity statin options, without the CYP3A4 dosing caveat that applies to simvastatin [15].

Switch the calcium channel blocker. If high-dose simvastatin is specifically needed and alternatives haven't worked, replacing amlodipine with a calcium channel blocker that doesn't inhibit CYP3A4 is an option, though this is usually a less practical first move given amlodipine's effectiveness and tolerability.

Which path makes sense depends on the individual's LDL target, other medications, and tolerance, this is a decision for the prescriber, not a generic recommendation, and the choice should not be made from this page alone.

Monitoring recommendations

The 2018 AHA/ACC cholesterol guideline does not recommend routine CK monitoring in asymptomatic statin patients [15]. Baseline CK before starting the combination still has practical value, since it gives a reference point if symptoms appear later. Clear counseling on how to recognize myopathy symptoms matters more than routine lab draws in an asymptomatic patient.

Liver function testing (ALT, AST) should follow the standard statin monitoring schedule: before starting or within about 12 weeks, after dose increases, and periodically thereafter [4]. Kidney function (serum creatinine, eGFR) is worth checking in patients who already carry elevated rhabdomyolysis risk, since impaired renal clearance of myoglobin is the mechanism by which rhabdomyolysis leads to acute kidney injury.

Other amlodipine drug interactions worth knowing

Amlodipine's CYP3A4 inhibition is not limited to simvastatin. Cyclosporine levels have been reported to rise when combined with CYP3A4 inhibitors including amlodipine, which is why cyclosporine blood levels typically require monitoring in that combination. Tacrolimus shows a related but generally smaller effect. Combining amlodipine with diltiazem or verapamil (other calcium channel blockers with their own CYP3A4 activity) can produce additive blood pressure lowering and is generally avoided without a specific reason.

Grapefruit juice is itself a CYP3A4 inhibitor, and patients on amlodipine plus simvastatin should be aware that regular grapefruit consumption could add to the interaction, though the combined magnitude of amlodipine, simvastatin, and grapefruit together has not been well characterized in controlled studies.

Amlodipine does not have clinically significant interactions with warfarin, metformin, ACE inhibitors, or ARBs at standard doses.

What pharmacists should screen for

Most pharmacy dispensing systems flag the amlodipine-simvastatin combination automatically once simvastatin exceeds 20 mg, and pharmacist-led dose corrections for statin-CYP3A4 interactions are a commonly described part of community pharmacy practice. A specific figure for how many dispensing events this prevents nationally each year was not identified in a form we could verify for this page, so we are not repeating a precise number here.

Pharmacists filling a new simvastatin prescription should check the profile for amlodipine, diltiazem, verapamil, amiodarone, and ranolazine, all of which carry simvastatin dose restrictions. The reverse matters too: if amlodipine is newly added to a patient already on simvastatin 40 mg or 80 mg, that warrants a call to the prescriber. Hospital discharge is a particularly high-risk point for this to slip through, since formulary substitutions can land a patient on a higher simvastatin dose than they were on before admission.